Related Experiment Video
Updated: Apr 5, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
[Molecular target therapies for skin cancers]
Abstract:
Over the three decades, advances in the fields of cancer genetics and immunology have elucidated mechanisms that cause the growth of cutaneous malignancies. This has contributed to the rational design of molecular target therapies. In this review, the molecular pathways and cancer immunology critical to the development of cutaneous malignancies are discussed. Included is a review of the following novel pharmacologic agents; BRAF inhibitors, MEK inhibitors, anti-CTLA-4 antibody and anti-PD-1 antibodies for melanoma, cetuximab and gefitinib for squamous cell carcinoma, vismodegib for basal cell carcinoma and nevoid basal cell carcinoma syndrome, imiquimod for extramammary Paget's disease, imatinib for dermatofibrosarcoma protuberans and vorinostat and mogamulizumab for cutaneous T-cell lymphoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

